PDCD1LG2 and melanoma: In conclusion, our systematic examination of plasma EV protein profiles in melanoma patients treated with ICIs highlights EV membrane PD‐L2 offers a promising predictor as a blood‐based biomarker for predicting and monitoring immunotherapeutic outcomes.